Vendor evaluation checklist Third-party COA from an accredited lab: The certificate of analysis should come from a laboratory independent of the vendor, carrying ISO 17025 accreditation or equivalent. The lab name, accreditation number, and contact should be verifiable. Batch traceability: The COA should match the specific batch number on the product you are purchasing. A COA that is undated or not tied to a batch offers limited assurance about what is in the vial you receive. Purity and identity testing: Look for HPLC purity data (ideally above 98%) and mass spectrometry or amino acid analysis confirming the peptide's identity, not just purity by a single method. Claims review: A vendor making treatment, outcome, or curative claims about sermorelin is marketing outside the legal scope of either research compounds or compounded drugs. Strong claims are a signal, not a feature. Compounding vs. research labeling: Compounded sermorelin requires a valid prescription and a licensed compounding pharmacy. Research-labeled sermorelin sold without a prescription is in a distinct and less regulated category. Understanding which you are purchasing matters for both legal and quality reasons. Return and verification policy: Reputable research vendors typically offer visible contact information, verifiable business addresses, and a clear process for batch verification inquiries. Affiliate disclosure: The link below is a paid affiliate relationship. We earn a commission if you purchase through it. This relationship did not influence our evaluation of sermorelin or the vendor criteria above. See our full disclosure policy . Looking for a vendor that meets these criteria?

Sermorelin: What It Is, the Evidence, and How to Evaluate It

Compound explainer · GH axis

Sermorelin: what it is, the evidence, and how to evaluate it

Sermorelin has a regulatory history unlike almost any other compound in this space. It was once a legitimate, FDA-approved drug for children. Then it was quietly withdrawn from the US market. Today it circulates primarily as a compounded or research compound, and the gap between those three chapters matters a great deal when evaluating what vendors are selling and what evidence actually exists.

Medical review by M. Cho, PharmD Compounding specialist · Updated June 3, 2026 · 12 min read · 9 cited sources

Research peptide vials on a laboratory bench — **Research context:** Sermorelin's prior FDA approval was for a pediatric indication, not adult use. The compounded versions sold today are not equivalent to the original approved drug and have not gone through the same approval process.

What the research shows

Sermorelin is a synthetic analog of the first 29 amino acids of endogenous GHRH, the hormone that stimulates pituitary GH release
In children with idiopathic GH deficiency, the original approved drug (Geref) produced documented increases in IGF-1 and growth velocity in clinical trials
Small adult studies have observed GH pulse amplitude changes following sermorelin administration
The mechanism of action (GHRH receptor agonism) is well established and understood at a pharmacological level
Unlike exogenous GH, GHRH analogs preserve the pituitary's own regulatory feedback loops in animal and early human research

What remains unknown

Long-term safety and efficacy in adults: no large, randomized, controlled trials in adult populations exist
Whether compounded sermorelin produces outcomes equivalent to the original pharmaceutical-grade Geref
Purity and potency consistency across research and compounding vendors: batch variation is a known concern
The clinical significance of the GH pulse changes observed in small adult studies
Interaction effects when combined with other peptides, a common practice that is almost entirely unstudied

What sermorelin is

Sermorelin is a synthetic peptide comprising the first 29 amino acids of growth hormone releasing hormone (GHRH), the signaling molecule the hypothalamus uses to tell the pituitary gland to secrete growth hormone (GH). Because it carries the biologically active N-terminal fragment of GHRH, sermorelin can bind to GHRH receptors on pituitary somatotroph cells and trigger GH release.

That mechanism is distinct from taking exogenous GH directly. Exogenous GH bypasses the pituitary entirely and delivers GH independent of the body's own feedback systems. Sermorelin, by contrast, works upstream: it asks the pituitary to produce GH in pulses that are still subject to the body's normal inhibitory signals, including somatostatin. In research and clinical framing, this is often described as a more physiologic route of GH axis stimulation, though the clinical significance of that distinction in adults has not been established in large controlled trials.

Regulatory history

Sermorelin was once an FDA-approved drug. It is no longer.

In 1997, the FDA approved sermorelin acetate under the brand name Geref (manufactured by Serono Laboratories) for the diagnosis and treatment of idiopathic growth hormone deficiency in children. The approval was based on clinical trials documenting increased growth velocity and IGF-1 levels in pediatric patients. In approximately 2008, Geref was voluntarily withdrawn from the US market by the manufacturer. The FDA lists it as a discontinued drug; the original approval is no longer active. Sermorelin today appears in two forms: as a compounded drug (legally prescribable by a licensed physician through an accredited compounding pharmacy under specific federal rules) and as a "research compound" sold without a prescription. These are not the same regulatory category as the original approved drug, and they are not interchangeable with it.

The withdrawal of Geref was a commercial decision, not a safety withdrawal. The manufacturer did not remove the drug because of identified safety problems; recombinant GH therapies had largely supplanted GHRH-based approaches in the pediatric market. That distinction matters: the absence of a current approval does not mean the compound was found unsafe, but it also does not mean its safety and efficacy profile in any current formulation has been validated through the same rigorous process as the original drug.

How sermorelin is discussed and marketed

Online discussion of sermorelin and much of the vendor marketing around it centers on three main areas: growth hormone optimization, body composition, and sleep quality. Here is how each is framed in the available research, and where the evidence actually stands.

Area 1

GH axis stimulation

The pharmacological mechanism is established. Sermorelin binds GHRH receptors and can increase GH pulse amplitude. Small studies in adults have measured increases in GH and IGF-1 following sermorelin administration. The question of what those changes mean clinically for healthy adults has not been answered by large controlled trials.

Limited human data

Area 2

Body composition

Some vendor marketing associates sermorelin with lean mass and fat reduction outcomes based on the known role of GH in metabolism. The clinical data for these outcomes specifically from sermorelin in adults is thin. GH has documented metabolic effects, but inferring the same effects from a GHRH analog in healthy adults requires data that does not yet exist at scale.

Preclinical / extrapolated

Area 3

Sleep quality

GH secretion is closely linked to slow-wave sleep, and some research has explored GHRH's role in sleep architecture. Studies looking specifically at sermorelin's effects on sleep in adults are limited. The connection between GHRH signaling and sleep is a real area of research; the specific clinical outcomes from sermorelin are not established.

Emerging / preliminary

Area 4

Recovery

Connective tissue repair and recovery framing often appears in the same marketing context as GH optimization compounds. No sermorelin-specific clinical trials on recovery outcomes in adults exist. This framing is extrapolated from the broader literature on GH's role in tissue maintenance.

Extrapolated only

This is the pattern worth understanding: sermorelin's mechanism is real and studied, but the gap between mechanistic understanding and demonstrated clinical outcomes in adults is wide. Most of what is marketed goes beyond what the current evidence base actually establishes.

How to evaluate a vendor selling sermorelin

Because sermorelin no longer exists as a commercially manufactured FDA-approved product, anyone purchasing it today is purchasing either a compounded pharmaceutical or a research-labeled compound. Both categories carry meaningful quality and compliance considerations that a certificate of analysis alone does not resolve.

Vendor evaluation checklist

Third-party COA from an accredited lab: The certificate of analysis should come from a laboratory independent of the vendor, carrying ISO 17025 accreditation or equivalent. The lab name, accreditation number, and contact should be verifiable.
Batch traceability: The COA should match the specific batch number on the product you are purchasing. A COA that is undated or not tied to a batch offers limited assurance about what is in the vial you receive.
Purity and identity testing: Look for HPLC purity data (ideally above 98%) and mass spectrometry or amino acid analysis confirming the peptide's identity, not just purity by a single method.
Claims review: A vendor making treatment, outcome, or curative claims about sermorelin is marketing outside the legal scope of either research compounds or compounded drugs. Strong claims are a signal, not a feature.
Compounding vs. research labeling: Compounded sermorelin requires a valid prescription and a licensed compounding pharmacy. Research-labeled sermorelin sold without a prescription is in a distinct and less regulated category. Understanding which you are purchasing matters for both legal and quality reasons.
Return and verification policy: Reputable research vendors typically offer visible contact information, verifiable business addresses, and a clear process for batch verification inquiries.

Affiliate disclosure: The link below is a paid affiliate relationship. We earn a commission if you purchase through it. This relationship did not influence our evaluation of sermorelin or the vendor criteria above. See our full disclosure policy.

Looking for a vendor that meets these criteria?

We reviewed vendors against the checklist above. The following link goes to a vendor whose COA documentation and batch traceability we found consistent with the standards described in this article. We have not evaluated the product itself, and this is not a clinical recommendation.

View vendor COA documentation Affiliate link

Sermorelin belongs to the GHRH analog class. Several related compounds are frequently discussed in the same context, sometimes combined with sermorelin in compounded preparations. Each has a distinct pharmacological profile and evidence base.

Sources

1 Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. PubMed
2 Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. PubMed
3 FDA Drug Databases. Sermorelin acetate (Geref). Discontinued from US market. FDA Orange Book. FDA Access Data
4 Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993;14(1):20-39. PubMed
5 Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. PubMed
6 Veldhuis JD, Bowers CY. Human GH pulsatility: an ensemble property regulated by age and gender. J Endocrinol Invest. 2003;26(9):799-813. PubMed
7 FDA. Human drug compounding. Regulatory information on section 503A and 503B compounding. FDA.gov
8 Brandenberger G, Gronfier C, Chapotot F, Simon C, Piquard F. Effect of sleep deprivation on overall 24 h growth-hormone secretion. Lancet. 2000;356(9239):1408. PubMed
9 Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed

Frequently asked questions

What is sermorelin?

Sermorelin is a synthetic peptide that replicates the first 29 amino acids of growth hormone releasing hormone (GHRH), the signal the hypothalamus uses to trigger GH secretion from the pituitary. It acts on GHRH receptors in the pituitary rather than delivering GH directly. It was first developed as a diagnostic and therapeutic agent for growth hormone deficiency in children and approved by the FDA in 1997 under the brand name Geref. That approval is no longer active; Geref was withdrawn from the US market around 2008.

Is sermorelin legal?

The answer depends on context. Sermorelin is not currently available as an FDA-approved, commercially manufactured drug in the United States. A licensed physician can legally prescribe compounded sermorelin through a licensed 503A compounding pharmacy for an individual patient. Research-labeled sermorelin sold without a prescription occupies a distinct and more legally ambiguous position. Purchasing or possessing it without a prescription is not the same as purchasing a prescription drug without a prescription, but it is not the same as purchasing an approved drug either. The legal landscape around research peptides is complex, actively evolving, and varies by jurisdiction. Consult a healthcare provider or legal professional for guidance specific to your situation.

What are sermorelin's claimed benefits?

Marketing around sermorelin typically focuses on GH axis stimulation, body composition, sleep quality, and recovery. The mechanism of action is pharmacologically established: sermorelin can increase GH pulse amplitude by binding GHRH receptors. Whether those GH changes translate into the clinical outcomes frequently marketed has not been established in large, controlled trials in adult populations. The strongest evidence for the compound involves its original approved use for growth hormone deficiency in children, a very different population and indication from current adult-focused marketing.

How does sermorelin differ from ipamorelin?

They work through different receptors. Sermorelin is a GHRH analog that binds GHRH receptors on pituitary cells and mimics the hypothalamic signal for GH release. Ipamorelin is a growth hormone secretagogue that works through the ghrelin receptor, a separate pathway that also results in GH release. The two compounds are sometimes combined in compounded preparations on the assumption of additive or synergistic GH stimulation through complementary mechanisms. That assumption is pharmacologically plausible but the combination has not been studied in controlled human trials. Both are currently sold primarily as compounded or research compounds without active FDA approval for the uses most commonly marketed.

Compound profile

Full name Sermorelin acetate

Class GHRH analog

Length 29 amino acids

Former brand name Geref (Serono Labs)

FDA approval status Discontinued (withdrawn ~2008). No current approval.

Current availability Compounded (Rx required) or research-labeled

Evidence level (adults) Limited human data. No large RCTs.

Original indication Pediatric idiopathic GH deficiency

The Pep Expert

Sermorelin: what it is, the evidence, and how to evaluate it

What sermorelin is

Sermorelin was once an FDA-approved drug. It is no longer.